Atrium Therapeutics, Inc. (RNA) stock
RNANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026
$6.92−0.06 (-0.86%)
Close on Nov 20, 2026Market cap $118.37MP/E –Yield –
Atrium Therapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$25.78M | – |
| Q2 FY2026 | Jun 30, 2026 | -$3.96M | – |
| Q1 FY2026 | Mar 31, 2026 | -$33.24M | – |
| Q3 FY2025 | Sep 30, 2025 | $833.00K | – |
| Q2 FY2025 | Jun 30, 2025 | -$12.17M | – |
| Q1 FY2025 | Mar 31, 2025 | -$11.10M | – |
See a number that looks wrong?